Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q8TBE9

UPID:
NANP_HUMAN

ALTERNATIVE NAMES:
Haloacid dehalogenase-like hydrolase domain-containing protein 4; Neu5Ac-9-Pase

ALTERNATIVE UPACC:
Q8TBE9; B3KP12; Q5JYN8; Q8TE97; Q9Y3N0

BACKGROUND:
The enzyme N-acylneuraminate-9-phosphatase, with its aliases Haloacid dehalogenase-like hydrolase domain-containing protein 4 and Neu5Ac-9-Pase, is integral to the degradation process of sialic acids. These acids are significant for the structural integrity of cell membranes and play roles in intercellular interaction and the immune response. The enzyme's function in breaking down sialic acids is essential for maintaining cellular health and communication.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of N-acylneuraminate-9-phosphatase offers a promising avenue for developing new therapeutic approaches. Given its critical role in sialic acid metabolism, which is vital for cell membrane composition and function, targeting this enzyme could lead to breakthroughs in treating diseases characterized by impaired cellular communication and immune response.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.